Aspen Aerogels, Inc. (NYSE:ASPN) Shares Acquired by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC boosted its position in Aspen Aerogels, Inc. (NYSE:ASPN) by 19.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 535,113 shares of the construction company’s stock after buying an additional 88,711 shares during the quarter. Rice Hall James & Associates LLC owned approximately 0.70% of Aspen Aerogels worth $14,817,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of ASPN. Point72 Hong Kong Ltd bought a new stake in shares of Aspen Aerogels in the 2nd quarter worth approximately $84,000. nVerses Capital LLC acquired a new stake in shares of Aspen Aerogels in the 2nd quarter worth about $95,000. Quent Capital LLC bought a new stake in Aspen Aerogels in the 3rd quarter valued at about $118,000. Point72 DIFC Ltd bought a new stake in Aspen Aerogels in the 2nd quarter valued at about $121,000. Finally, Public Employees Retirement Association of Colorado acquired a new position in Aspen Aerogels during the 2nd quarter valued at about $145,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Aspen Aerogels Price Performance

ASPN stock opened at $17.83 on Friday. The firm has a 50-day moving average of $24.53 and a two-hundred day moving average of $24.51. The firm has a market capitalization of $1.37 billion, a PE ratio of -1,783.00 and a beta of 2.16. The company has a current ratio of 3.46, a quick ratio of 2.82 and a debt-to-equity ratio of 0.23. Aspen Aerogels, Inc. has a one year low of $7.37 and a one year high of $33.15.

Aspen Aerogels (NYSE:ASPN) last posted its quarterly earnings data on Wednesday, August 7th. The construction company reported $0.21 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.16. Aspen Aerogels had a net margin of 0.39% and a return on equity of 0.74%. The firm had revenue of $117.80 million for the quarter, compared to analysts’ expectations of $101.99 million. During the same period in the previous year, the company posted ($0.22) EPS. The company’s quarterly revenue was up 144.4% compared to the same quarter last year. On average, analysts forecast that Aspen Aerogels, Inc. will post 0.21 earnings per share for the current year.

Insider Activity

In related news, CEO Donald R. Young sold 63,355 shares of the business’s stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $30.03, for a total transaction of $1,902,550.65. Following the transaction, the chief executive officer now directly owns 483,640 shares of the company’s stock, valued at approximately $14,523,709.20. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CFO Ricardo C. Rodriguez sold 32,465 shares of the stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $30.14, for a total value of $978,495.10. Following the transaction, the chief financial officer now owns 20,790 shares in the company, valued at approximately $626,610.60. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Donald R. Young sold 63,355 shares of Aspen Aerogels stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $30.03, for a total transaction of $1,902,550.65. Following the completion of the sale, the chief executive officer now owns 483,640 shares of the company’s stock, valued at $14,523,709.20. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.30% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on ASPN shares. TD Cowen boosted their price objective on Aspen Aerogels from $36.00 to $41.00 and gave the stock a “buy” rating in a research report on Tuesday, August 20th. HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of Aspen Aerogels in a report on Wednesday, October 16th. Benchmark reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Aspen Aerogels in a report on Thursday, August 8th. Piper Sandler lowered their target price on shares of Aspen Aerogels from $36.00 to $33.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 22nd. Finally, Barclays initiated coverage on shares of Aspen Aerogels in a research note on Tuesday, August 6th. They set an “overweight” rating and a $27.00 price objective on the stock. One analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Aspen Aerogels presently has a consensus rating of “Moderate Buy” and an average price target of $29.40.

Aspen Aerogels Profile

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.